Utah Medical Products, Inc. (NASDAQ:UTMD – Get Rating) Director Paul O. Richins sold 700 shares of the stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $93.47, for a total value of $65,429.00. Following the completion of the transaction, the director now owns 21,461 shares in the company, valued at approximately $2,005,959.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Utah Medical Products Price Performance
NASDAQ:UTMD opened at $92.74 on Monday. The business has a fifty day simple moving average of $93.64 and a two-hundred day simple moving average of $92.93. Utah Medical Products, Inc. has a 1 year low of $80.10 and a 1 year high of $109.50. The company has a market capitalization of $336.65 million, a P/E ratio of 19.69 and a beta of 0.19.
Utah Medical Products Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Thursday, July 6th. Stockholders of record on Friday, June 16th will be given a $0.295 dividend. This represents a $1.18 annualized dividend and a dividend yield of 1.27%. The ex-dividend date is Thursday, June 15th. Utah Medical Products’s dividend payout ratio (DPR) is presently 25.05%.
Wall Street Analysts Forecast Growth
Hedge Funds Weigh In On Utah Medical Products
Several hedge funds have recently made changes to their positions in UTMD. Belpointe Asset Management LLC purchased a new position in shares of Utah Medical Products in the fourth quarter valued at $40,000. Acadian Asset Management LLC purchased a new position in shares of Utah Medical Products in the first quarter valued at $40,000. BNP Paribas Arbitrage SA grew its position in shares of Utah Medical Products by 97.7% in the second quarter. BNP Paribas Arbitrage SA now owns 779 shares of the medical instruments supplier’s stock valued at $67,000 after purchasing an additional 385 shares in the last quarter. Lazard Asset Management LLC grew its position in shares of Utah Medical Products by 21.3% in the first quarter. Lazard Asset Management LLC now owns 837 shares of the medical instruments supplier’s stock valued at $75,000 after purchasing an additional 147 shares in the last quarter. Finally, BNP Paribas Arbitrage SNC grew its position in shares of Utah Medical Products by 33.5% in the third quarter. BNP Paribas Arbitrage SNC now owns 1,040 shares of the medical instruments supplier’s stock valued at $89,000 after purchasing an additional 261 shares in the last quarter. 70.04% of the stock is currently owned by hedge funds and other institutional investors.
About Utah Medical Products
Utah Medical Products, Inc engages in the manufacturing, developing, and marketing of disposable and reusable medical devices. It focuses on the healthcare of women and babies. Its products are used for blood pressure monitoring and blood collection, electrosurgery, gynecology, neonatal critical care, perinatology, and urology.
- Get a free copy of the StockNews.com research report on Utah Medical Products (UTMD)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for Utah Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Utah Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.